Atrial fibrillation in patient with high thrombotic risk: which therapy?
Fibrillazione atriale in paziente a elevato rischio trombotico: quale terapia?
We report the case of an elderly patient suffering for about 20 years of hypertensive cardiac hypertrophy, carotid and peripheral vasculopathy. The patient, initially treated with oral anticoagulant therapy (dicumarol) due to relapsing atrial fibrillation, is an example of long-term use of dabigatran, dictated by safety concern in a patient at high risk of bleeding: as demonstrated by the RE-LY trial, dabigatran 110 mg / day has a preventive effect on cerebral events similar warfarin but with a lower incidence of bleeding. In this case, at high risk both thrombotic and hemorrhagic, the choice of dabigatran was successful in the long term (Cardiology).
Copyright (c) 2018 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors contributing to AboutOpen agree to publish their articles under the Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.